Abstract. Aberrant epigenomic alterations include incorrect histone modifications involving altered expression of chromatin-modifying proteins. They contribute to gene silencing and carcinogenesis. The nature of the epigenomic alterations occurring with prostate cancer remains to be fully identified. The acetylation status of histone H3 in human prostate cancer cells was assessed with multiple acetylation sites at N-termini. In contrast to the non-malignant prostatic cell lines RC165N/h and RC170N/h which possess stem cell properties, cancer cell lines LNCaP, DU-145, and PC-3 were either not acetylated or reduced in density (50-70%), at N-termini lysines 9, 14, 18, and 23 of histone H3. Deficient acetylation of histone H3 was similarly detected with clinical prostatic adenocarcinomas as compared to normal tissues. Cancer cell lines and adenocarcinomas exhibited varied acetylation status at particular lysines, indicating the possible presence of deacetylation patterns reflecting individual cancer cell clones. A significantly elevated activity of histone deacetylases (HDACs) was determined in both cancer cell lines and adenocarcinomas. Inhibition of HDACs enhanced histone acetylation and p21 gene expression, indicating that excessive HDAC activity is a requisite for deficient histone acetylation. Deficient histone acetylation involving excessive HDAC activity may represent epigenomic features of prostate cancer cells, and the aberrant enzyme activity is probably an underlying cause of disrupting the epigenomes of normal prostatic cells.
Introduction
Two copies of each histone protein H2A, H2B, H3, and H4 form an octamer core of nucleosome, wrapped around by 1.65 turns of DNA. Each form of histone has variants as some amino acids are enzymatically modified. The posttranslational modifications include methylation, acetylation, phosphorylation, ubiquitylation, and others that may alter the structural properties of the protein, as well as the chromatin architecture that may be transmissible to the next generations as epigenetic inheritance. The various types of histone modifications and their combinations are considered the specific instructions for the chromatin functions and nuclear processes (1, 2) . Most of the histone modifications occur around the flexible N-and C-termini. The N-termini are highly basic, enriched with amino acids that could be acetylated and methylated. The N-terminal loops are intertwined with the DNA, passing through the channels in the superhelix and protruding from the surface of nucleosomes (3) . The different types of histone modifications have been linked with distinct functions. Acetylation has been known to alter the structural property of nucleosomes and chromatin, enhancing gene expression as well as DNA repair and cytokine-activated signal transduction (4) (5) (6) . The lysine acetylation marks may be interpreted by interacting with specific effector modules bromodomain complexes (7, 8) , which may mediate chromatin remodeling and transcriptional regulation.
The level of acetylation is maintained by a pair of opposing enzymes, the acetyltransferases and the histone deacetylases (HDACs). Aberrant activities of these enzymes such as excessive recruitment of HDACs, and mutation in acetyltransferases, have been implicated in gene silencing in cancer (9) (10) (11) . There have been cancer clinical trials employing HDAC inhibitors, but the scientific rationale for treating prostate cancer has not been fully presented. Our recent experiments using the isothiocyanates as HDAC inhibitors, in prostate cancer cells, revealed that they induced hyperacetylation of histones H3 and H4, resulting in growth arrest and apoptosis (12, 13 (14) . We examined the lysine residues, known to be acetylated in vivo, located from the N-terminus extending near the channel in the seperhelix where the histone protrudes to the surface of nucleosome (15) . In this study we present the profiles of histone H3 N-terminal acetylation in prostate cancer cell lines and in clinical adenocarcinomas. They show a severe deficiency of acetylation which is distinct from the profile of non-malignant prostatic cells. The deficient acetylation is caused by excessive HDAC activity and could be reversed by HDAC inhibition.
Materials and methods
Cell culture and tissues. Prostate cancer cell lines LNCaP, DU-145, and PC-3 were maintained in RPMI-1640 with 10% heat-inactivated fetal calf serum. Some of these cultures were exposed to 2 mM sodium butyrate for one day. Two telomerase-immortalized non-malignant human prostate epithelial cells, RC165N/h and RC170N/hclone 7 (RC170N/h) that retain multipotent stem cell properties (16, 17) , were kindly provided by Dr Johng S. Rhim, Uniformed Services University of the Health Sciences, Bethesda, MD. They were maintained in serum-free keratinocyte medium supplemented with bovine pituitary extract and recombinant epidermal growth factor (Life Technologies, Inc.). Prostate specimens were from discarded tissues after pathological examinations according to the internal review board protocol. The adenocarcinoma specimens were obtained from radical prostatectomy and the tumors reported were determined pathologically with the following grades and stages. Specimens 1-6, presented in the report were respectively moderately differentiated (Gleason score 6, stage T 0 N 0 ); moderately differentiated (Gleason score 6, stage T 2b ); poorly differentiated (Gleason score 6-7, stage T 2b ); moderately differentiated (Gleason score 5, stage T 2b ); moderate to poorly differentiated (Gleason score 6, stage T 2c ); and moderate to poorly differentiated (Gleason score 7, stage T 2c ). Two prostatic tissues (normal) were determined pathologically as being non-cancerous, without hypertrophy, and no diagnostically abnormality.
Histone modification and detection. Lysates from cell cultures or tissues were prepared in the presence of HDAC inhibitor sodium butyrate at 5 mM final concentration as previously described. Histones were isolated using an acid extraction procedure (18, 19) . The procedures for quantitative Western blotting were performed as previously described (18), with site-specific antibodies against acetylated lysines 4, 9, 14, 23, or 27 of histone H3 (Millipore). For confocal immuno- fluorescence microscopy, DU-145 cells grown on chamber slides were treated one day without or with 2 mM sodium butyrate, then fixed, permiabilized, blocked in BSA and incubated with a rabbit anti-histone H3 for 1 h. A fluoreceinconjugated F(ab') 2 fragment of goat anti-rabbit Ig was used as a second antibody and the DNA counterstained with propidium iodide (PI) to visualize the nuclei of all cells. Images were captured using an MRC 1024 ES confocal laser scanning microscopy system. Identical image settings were used for experimental conditions.
HDAC activity. HDAC activity of classes I, II, and Sirt1 was detected with a previously described procedure using a HDAC assay kit (Biomol International) (18) . The assay uses a synthetic acetylated lysine side chain as a substrate to react with the deacetylase samples in a 96-well microplate. Deacetylation of the substrate allows its detection with a developer that produces a fluorophore. A HeLa cell nuclear extract with known HDAC activity was used as a positive control. Some samples were added with 1 μM trichostatin A (TSA), a known HDAC inhibitor. The reaction mixture was added with the substrate with concentrations at or below the Km, and incubated at room temperature before adding the developer containing 1 μM TSA. The reaction was determined with a Cary Eclipse fluorimeter using wavelength 360 nm and detection of emitted light at 460 nm. The fluorescence was expressed as arbitrary units (AU). The mean values of fluorescence for HDAC activity from the malignant and non-malignant cells were statistically compared with the two-tailed Student's t-test, and a P<0.05 was considered to be statistically significant.
Results

Deficient histone acetylation in prostate cancer cells.
The status of acetylation of histone H3 from three prostate cancer cell lines, LNCaP, DU-145 and PC-3, was compared to two non-malignant prostatic cell lines RC165N/h and RC170N/h, which were cloned from telomerase-immortalized primary non-malignant prostate tissues. They express embryonic stem cell marker Oct-4, prostate stem cell markers CD133, CD44 and retain the properties of multipotent stem cells including differentiating into multiple prostatic tissues (16) . Acetylation levels of the N-terminal lysines 9, 14, 18, or 23 of histone H3 were examined by Western blotting. Fig. 1 depicted that cells from the two non-malignant cell lines were acetylated, with similar levels at the N-terminal lysines. In contrast, the acetylation density of the three cancer cell lines was significantly lower, at each of these lysines. There were clear variations of acetylation levels at particular lysine sites, among the cancer cell lines. The LNCaP and DU-145 cells were more similar, comparing to the PC-3 cells. They lack acetylation at lysine 14, and the levels of acetylated lysines 9, 18, and 23 were about one third of those in the nonmalignant cells (Fig. 1) . The PC-3 cells were clearly acetylated at lysine 14, and acetylation on lysines 9, 18 and 23 was barely detectable. The results demonstrated distinct patterns of histone acetylation between prostate cancer and nonmalignant cell lines, with the cancer cells either reduced, or absent in the N-terminal acetylation.
Excessive HDAC activity and the effects of HDAC inhibition. A deficient histone acetylation would imply an excessive deacetylation, which could be caused by an elevated activity of the deacetylase enzymes. The total HDAC activity of classes I, II, and Sirt1 from each cell culture was quantified, and Fig. 2A depicted clearly that all three cancer cell lines exhibited higher HDAC activity, per unit amount of cellular protein, compared to the non-malignant cell lines. The difference of HDAC activity between RC165N/h and RC170N/h was not statistically significant (P=0.08), while the HDAC activity in the cancer cells LNCaP, DU-145, or PC-3 was significantly higher than either RC165N/h or RC170N/h (P<0.05). When the cellular proteins were treated with 1 μM TSA, an inhibitor of HDACs, the great majority of the HDAC activity was blocked. These results indicated a higher HDAC activity in the prostate cancer cells. Fig. 2B shows that the LNCaP cells had ~12-23% higher activity than the two non-malignant cells, the DU-145 cells were 35-42% higher, and the PC-3 cells 30-38% higher. To further determine that the lower level of histone acetylation is related to an excessive deacetylase activity, the status of acetylation was examined after the cancer cells were treated with sodium butyrate, an inhibitor of HDACs. Fig. 3A shows that the acetylation levels of histone H3, and those at lysines 18 and 23 in LNCaP and DU-145 cells, were clearly increased after sodium butyrate treatment, when compared to that of non-malignant cells RC165N/h. When analyzed with confocal fluorescent microscopy ( Fig. 3B ), DU-145 had background level of acetylated histone H3 in the nuclei. The sodium butyrate treatment enhanced fluorescent staining to the level of the non-malignant cells RC165N/h. These findings verified the results that an aberrantly elevated HDAC activity may be responsible for the deficient acetylation in prostate cancer cells.
It has been reported that highly acetylated histones, as induced by HDAC inhibitors, are associated with the activation of the p21 gene, inhibitor of cyclin-dependent kinases (20, 21) . The expression level of p21 in the prostate cancer cell lines, without or with the treatment of sodium butyrate was examined. Fig. 3B shows convincingly that as the result of sodium butyrate treatment, the protein levels of p21 were significantly up-regulated, in both LNCaP and DU-145 cells.
The status of histone H3 acetylation was examined in eleven prostate adenocarcinoma specimens, and compared to four normal prostate specimens. Acetylation at multiple sites of histone H3 was severely deficient in all the adenocarcinomas examined, and representative data are described in Fig. 4A . Comparing to the normal specimens, acetylation density of histone H3 from the adenocarcinomas was generally weak, and were absent at lysines 14 and 23 for most of the specimens. There were some variations of the deficiency among the adenocarcinomas. For example, specimens 1 and 6 lost acetylation at lysine 9 as compared to that of specimens 2, 3, and 4. Fig. 4B illustrates the HDAC activity of these prostate specimens as measured per unit of cellular proteins. Each adenocarcinoma specimen had higher activity than the normal specimens, with the difference statistically significant (P<0.02). The results indicate that the HDAC enzyme activity may be elevated in the prostatic adenocarcinomas.
Discussion
Evidence is presented in this report that prostate cancer cells have either lost acetylation completely or are reduced in levels, at multiple acetylation sites of histone H3 N-termini, revealing a deficient state of histone acetylation. For each analysis, four consecutive lysines starting from the N-termini were examined for the status of histone acetylation. This method generated more complete profiles of acetylation than examining single lysines. The experimental results have clearly demonstrated the presence of a deficient histone acetylation along with an excessive deacetylase activity in both prostate cancer cell lines and clinical adenocarcinomas, as compared to non-malignant prostatic cell lines and tissues. The non-malignant prostatic cell lines, used for comparative analysis, retain embryonic stem cell markers and multipotent stem cell properties (16, 17) . Whether the incorrect histone acetylation in the cancer cells implies a disruption of the normal stem cell epigenomes remains to be determined.
One potential mechanism for initiating deficient histone acetylation, and establishing the marks as irreversible epigenomic changes, could be that the expression of the chromatin-modifying proteins and enzymes, which maintain the balance of histone acetylation, become abnormal. This possibility was examined with the HDAC activity, which was determined to be elevated with statistical significance, in both cancer cell lines and adenocarcinomas examined. Additionally, the low level histone acetylation could be consistently up-regulated after HDAC inhibition, further supporting an excessive deacetylase activity. This finding is significant since there is no prior report clearly defining an elevated HDAC activity in clinical prostate tumors. Since the HDAC activity measured in this study represented the sum of multiple HDAC species, this analysis therefore could not decipher the activity levels of individual enzymes. How the activity levels of individual HDACs affect the N-terminal lysines or global acetylation, remains to be investigated. This will shed light on the difference seen between the magnitude of increased HDAC activity and the decreased acetylation at the N-termini of histone H3. The current findings are in line with other reports. Patra et al (22) described that HDAC activity was 2-to 3-fold higher in prostate cell lines TSUPr1 and DuPro, than a benign prostatic hyperplasia cell line BPH-1, but the effect on histone acetylation was not described. Seligson et al (23) described a potential association of a lower density of histone acetylation at H3K9 or H3K18 with certain grades of prostate adenocarcinomas, but no measurement was made with enzymes regulating acetylation. An excessive recruitment of HDAC activity was also described with other cancers including leukemic cells (24) .
The experimental results demonstrated that the prostate cancer cell lines may have individual patterns of histone deacetylation, i.e., lost or reduced acetylation at particular lysine residues. The LNCaP and DU-145 cell lines were shown to have a similar pattern that is distinct from the PC-3 cells. Whether the individual deacetylation profiles represent the aberrant acetylation marks of the original clones, transmitted as epigenetic inheritance, or reflect those deacetylation marks acquired during tumor progression, remains to be analyzed. The observations imply that each pattern of deacetylation may represent an epigenetic mark of the cell type. The combination of the status of histone acetylation and the activity level of HDACs could be yet another characteristic as a cell marker. The current initial analyses have established the methodology used, i.e., examining multiple acetylation sites in combination with HDAC activity, which could be employed for further analyses of the cells of adenocarcinomas and pre-cancerous lesions. The new information may further reveal any association of tumor developmental stages with histone deacetylation profiles of cancer cells.
The experimental results imply the presence of dysregulated epigenomes in prostate cancer cells, which include an excessive HDAC activity and deficient histone acetylation. Since HDACs are present in the complexes of transcriptional co-regulators such as mSin3A and N-CoR which are required for repressing target genes (25, 26) , the use of HDAC inhibitors could de-repress the genes that are inactivated due to hypoacetylation. Reactivation of the cell cycle regulator p21 gene in prostate cancer cells, after inhibiting HDACs, may represent an example in this regard. These findings point to the potential of HDAC inhibitors to restoring histone acetylation and their functions to a more normal state.
